Key result
Atorvastatin reduced central arterial stiffness (PWV) from 10.37 to 9.10 m/sec at 12 months (p<0.001) in men with type 2 diabetes, with no significant difference between 10 mg and 80 mg doses.
Why the study?
Does atorvastatin reduce central arterial stiffness in a dose-dependent manner in male patients with type 2 diabetes?
RCT (n=51)
Does atorvastatin reduce central arterial stiffness in a dose-dependent manner in male patients with type 2 diabetes?
Atorvastatin reduces central arterial stiffness and vascular inflammation in male patients with type 2 diabetes, though without a dose-dependent effect between 10 mg and 80 mg.
Atorvastatin lowers PWV in men with type 2 diabetes independent of dose; confirms arterial benefit but challenges dose-response superiority.
Statin therapy improves lipid profiles and reduces vascular inflammation, but its effects on central arterial stiffness in type 2 diabetes are unclear. The aim of this study was to determine whether statin therapy reduces central arterial stiffness, in a dose-dependent manner, in male patients with type 2 diabetes. Fifty-one patients ceased statin therapy for 6 weeks, followed by randomisation to either 10 or 80 mg of atorvastatin. At randomization, 3 and 12 months, central arterial stiffness was measured via carotid-femoral pulse wave velocity (PWV), along with serum markers of vascular inflammation including high-sensitivity c-reactive protein (hsCRP) and osteoprotegerin (OPG). PWV decreased from 10.37 ± 1.30 to 9.68 ± 1.19 m/sec (p < 0.01 from baseline) at 3 months and 9.10 ± 1.17 m/sec (p < 0.001 from baseline) at 12 months. hsCRP and OPG decreased significantly at 3 and 12 months. Reductions in PWV did not differ significantly between the groups. Baseline PWV and OPG values correlated strongly (r = 0.48, p < 0.01), as did their response to atorvastatin over 12 months (r = 0.36 delta-OPG and delta-PWV, p < 0.01). Atorvastatin therapy appeared to reduce central arterial stiffness in male type 2 diabetes, with no dose-dependent effect observed. The correlation observed between reductions in PWV and OPG suggests that atorvastatin reduces PWV via direct anti-inflammatory effects on the vasculature.
No takes yet. Share an insight, caveat, or question.
Davenport et al. (2015) conducted an RCT in Type 2 Diabetes (n=51). Atorvastatin vs. 10 mg vs 80 mg was evaluated on Central arterial stiffness (carotid-femoral pulse wave velocity). Atorvastatin reduced central arterial stiffness (PWV) from 10.37 to 9.10 m/sec at 12 months (p<0.001) in men with type 2 diabetes, with no significant difference between 10 mg and 80 mg doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: